Aug 6, 2024 8:00am EDT Tonix Pharmaceuticals Announces Publication in Microorganisms of Technology that Expands Company’s Capabilities in Generating Potential Therapeutic Fully Human Antibodies Against SARS-CoV-2 and Other Pathogens
Aug 1, 2024 7:45am EDT FDA Recognizes Fibromyalgia as a 'Serious Condition' And Fast-Tracks New Drug Candidate
Jul 31, 2024 8:00am EDT Tonix Pharmaceuticals Announces Potential Positive Impact of the U.S. National Academies (NASEM) New Definition of Long COVID on the Size of the Fibromyalgia Market for Tonmya™
Jul 30, 2024 8:00am EDT Tonix Pharmaceuticals Announces Poster Presentation at the IASP 2024 World Congress on Pain
Jul 25, 2024 8:00am EDT Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia
Jul 24, 2024 7:45am EDT Beyond "One Bug, One Drug" - Tonix Pharmaceuticals Secures Up To $34 Million In Funding From The U.S. Department Of Defense To Develop a Broad-Spectrum Antiviral
Jul 17, 2024 8:00am EDT Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of Fibromyalgia, is Planning Expected Launch in 2H 2025
Jul 9, 2024 9:15am EDT Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering